Y-mAbs Therapeutics (YMAB) Expected to Announce Quarterly Earnings on Tuesday

Y-mAbs Therapeutics (NASDAQ:YMAB) will likely be announcing its earnings results before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $26.70 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Y-mAbs Therapeutics Trading Down 0.5 %

YMAB opened at $5.69 on Tuesday. Y-mAbs Therapeutics has a 12 month low of $5.47 and a 12 month high of $20.90. The stock has a 50-day moving average of $6.84 and a 200 day moving average of $10.87. The firm has a market cap of $254.85 million, a P/E ratio of -10.54 and a beta of 0.67.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on YMAB shares. Wedbush restated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Friday, January 10th. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Finally, Oppenheimer assumed coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $20.89.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.